The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Organizing pneumonia pattern (an area or areas of consolidation on imaging)
Publications
Rituximab-induced bronchiolitis obliterans organizing pneumonia.
Case reports in medicine. 2012;2012:680431
Recurrent fevers, cough, and pulmonary opacities in a middle-aged man.
Chest. 2010;137(6):1465-9
Cryptogenic organizing pneumonia after rituximab therapy for presumed post-kidney transplant lymphoproliferative disease.
Pediatric nephrology (Berlin, Germany). 2010;25(6):1163-7
Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature.
Pediatric pulmonology. 2009;44(9):922-34
Rituximab-induced lung disease: A systematic literature review.
The European respiratory journal. 2010;35(3):681-7
Organizing pneumonia after rituximab therapy: Two cases.
Joint bone spine. 2008;75(3):362-5
Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.
Hematological oncology. 2006;24(4):234-7